Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roi Weiser

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Practical Radiation Oncology|December 11, 2025
Surgical Reconstruction Toxicity Following Hypofractionated Adjuvant Radiation Therapy for Primary Cutaneous MelanomaNoel X Yang, Gianna L Rosamilia, Andrew J Arifin, et al.
Annals of Surgical Oncology|May 26, 2026
The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with MicrosatellitosisAnjali Devireddy, Yifan Yi, Kelsey N Nordlund, et al.
Annals of Surgical Oncology|June 1, 2026
ASO Visual Abstract: The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma with MicrosatellitosisAnjali Devireddy, Yifan Yi, Kelsey N Nordlund, et al.
Annals of Surgical Oncology|March 16, 2026
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.
Annals of Surgical Oncology|April 24, 2026
Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.
Nature Cancer|February 11, 2022
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancerNancy Gavert, Yaara Zwang, Roi Weiser, et al.
Frontiers in Oncology|November 3, 2022
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanomaJoel Ho, Jane Mattei, Michael Tetzlaff, et al.
NPJ Genomic Medicine|May 23, 2026
Germline variants in cancer susceptibility genes among patients with mucosal melanomaAfsaneh Amouzegar, Xiaogang Wu, James P Long, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Science (New York, N.Y.)|May 30, 2020
The human tumor microbiome is composed of tumor type-specific intracellular bacteriaDeborah Nejman, Ilana Livyatan, Garold Fuks, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Practical Radiation Oncology|December 11, 2025
Surgical Reconstruction Toxicity Following Hypofractionated Adjuvant Radiation Therapy for Primary Cutaneous MelanomaNoel X Yang, Gianna L Rosamilia, Andrew J Arifin, et al.
Annals of Surgical Oncology|May 26, 2026
The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with MicrosatellitosisAnjali Devireddy, Yifan Yi, Kelsey N Nordlund, et al.
Annals of Surgical Oncology|June 1, 2026
ASO Visual Abstract: The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma with MicrosatellitosisAnjali Devireddy, Yifan Yi, Kelsey N Nordlund, et al.
Annals of Surgical Oncology|March 16, 2026
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.
Annals of Surgical Oncology|April 24, 2026
Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.
Nature Cancer|February 11, 2022
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancerNancy Gavert, Yaara Zwang, Roi Weiser, et al.
Frontiers in Oncology|November 3, 2022
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanomaJoel Ho, Jane Mattei, Michael Tetzlaff, et al.
NPJ Genomic Medicine|May 23, 2026
Germline variants in cancer susceptibility genes among patients with mucosal melanomaAfsaneh Amouzegar, Xiaogang Wu, James P Long, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
Science (New York, N.Y.)|May 30, 2020
The human tumor microbiome is composed of tumor type-specific intracellular bacteriaDeborah Nejman, Ilana Livyatan, Garold Fuks, et al.
Pageof 3